Identification of biomarkers of response and toxicity to chemo/radiotherapy
As chemotherapy for oesophageal cancer is associated with a significant risk of side effects, and actually only benefits some individuals, the ability to identify those individuals that might benefit from chemotherapy vs. those that won’t benefit or may even be harmed is critical knowledge for improving the outcome for individuals with oesophageal cancer. This research is trying to discover a blood test that can be used to predict response to chemotherapy and the risk of major side effects.
What we aim to achieve
To develop a blood test that will predict response and toxicity to chemotherapy in individuals with oesophageal cancer, so that we can better tailor cancer treatment to individuals who are likely to benefit and not be harmed
Our next steps and milestones
Funding has allowed initial pilot work to be undertaken which facilitated a larger grant from NHMRC. This work is ongoing, but early outcomes suggest that differences can be identified which might allow treatments to be better tailored to specific individuals.
What motivates me
Oesophageal cancer has a poor outlook. It is critical to offer treatments which can improve the outcome for patients with oesophageal cancer.
My message to supporters
Funding allowed initial pilot work to be undertaken which has led to a subsequent larger grant from NHMRC. This work has potential to change the way we use chemotherapy in oesophageal cancer.